Abstract:Background/Purpose Genome-Wide Association Studies (GWAS) have unveiled over 1000 risk variants for lupus, predominantly situated in non-coding genomic regions. Their functional roles, especially their potential impacts on the dysregulated type I interferon pathway inherent in lupus, remain largely uncharted. To bridge this knowledge gap, our study employs CRISPR/Cas9 technology, enabling a deeper exploration into the functional implications of these risk loci. Methods Our novel strategy entailed CRISPR-based screening for functional variants that regulate the type I interferon pathway. We collected all known SLE-associated SNPs and expanded them through linkage disequilibrium in the population where the SNP was reported. We designed an sgRNA library covering these SLE-associated SNPs and developed a cellular model using U-937, Jurkat, and Raji cells that stably express the CRISPR/Cas9-ISRE-GFP and CRISPR/SAM-ISRE-GFP systems. Post-transduction with the sgRNA lentiviral library, we sorted cells based on GFP intensity and extracted and sequenced DNA from these sorted cells. The functional variants were identified and characterized using multi-omics analysis (eQTL data, HiC data, RNA-sequencing data). We validated the function of the rs11152966-located region and identified PRDM1 as the target gene of rs11152966 through integration of advanced technologies like capture-HiC, CRISPR-SAM, and prime editing technology. Results We've characterized the comprehensive landscape of functional SNPs related to lupus that regulate the Type I interferon pathway (figure 1). Notably, we discovered that the majority of these functional variant regions are cell type-specific (figure 1). Utilizing the CRISPR/Cas9 and CRISPR/SAM systems effectively, we found these tools to have complementary benefits in the identification of these functional variants. Furthermore, these functional variant regions were found to be associated with the expression of critical regulators within the JAK-STAT pathway and interferon-stimulated genes (ISGs) (figure 2). Importantly, we observed a correlation between the expression of transcription factors disrupted by these functional variants and the expression of ISGs in SLE patients (figure 2). One standout finding was the negative regulatory effect on the Type I interferon pathway upon activation of the region containing the SNP rs11152966 (figure 3). This region, inclusive of the SNP, forms a gene loop with the PRDM1 promoter, thereby managing PRDM1 expression (figure 3). Additionally, we provided evidence that PRDM1 acts as a novel negative regulator of the Type I interferon pathway (figure 3). Lastly, our research revealed a link between the presence of the risk allele T and a reduction in PRDM1 expression. This reduced expression appears to be due to the allele T's effect on the binding of the transcription factor SPI1 (figure 3). Conclusion Our study leveraged advanced gene-editing tools to elucidate the landscape of functional SNPs in lupus, revealing their cell type-specific regulation of the Type I interferon pathway and their influence on key genes in the JAK-STAT pathway. Notably, we highlighted the significant role of SNP rs11152966 and its target gene PRDM1 in regulating the interferon pathway in lupus.

704 Global Identification of Lupus Genetic Risk Variants Modulating the Type I Interferon Pathway Through CRISPR-based Genomic Screening

High-throughput identification of functional regulatory SNPs in systemic lupus erythematosus

Integrative Functional Genomics Identifies Systemic Lupus Erythematosus Causal Genetic Variant in the IRF5 Risk Locus.

CRISPRa screen on a genetic risk locus shared by multiple autoimmune diseases identifies a dysfunctional enhancer that affects IRF8 expression through cooperative lncRNA and DNA methylation machinery

SLE Non-Coding Genetic Risk Variant Determines the Epigenetic Dysfunction of an Immune Cell Specific Enhancer That Controls Disease-Critical Microrna Expression

A multilayered post‐GWAS analysis pipeline defines functional variants and target genes for systemic lupus erythematosus (SLE)

Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery

Three-Dimensional Chromosomal Landscape Revealing Mir-146A Dysfunctional Enhancer in Lupus and Establishing a CRISPR-Mediated Approach to Inhibit the Interferon Pathway

Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility

Identification of LncRNA Linc00513 Containing Lupus-Associated Genetic Variants as a Novel Regulator of Interferon Signaling Pathway.

LO-028 Functional Dissection of Dysregulated Enhancers Influencing SLE Critical Gene Expression

Global discovery of lupus genetic risk variant allelic enhancer activity

KLF2 enhancer variant rs4808485 increases lupus risk by modulating inflammasome machinery and cellular homoeostasis

modulates lupus risk via negative regulation of interferon response

-eQTL mapping prioritises as a negative regulator of interferon response at a lupus risk locus

Deciphering cell-specific genetic insights: Unraveling the immunogenetic landscape of systemic lupus erythematosus

Non-coding DNA Variants for Risk in Lupus.

Peripheral mononuclear cells and systemic lupus erythematosus association: Integrated study of single-cell sequencing and mendelian randomization analysis

Clinical Implications of a New DDX58 Pathogenic Variant That Causes Lupus Nephritis Due to RIG-I Hyperactivation

Genome-Wide Identification of Cell Type-Specific Susceptibility Genes for SLE Through the Analysis of RNA Modification-Associated SNPs